The aim was to evaluate the expression of HER-2/neu in oral squamous cell carcinoma (OSCC) as a potential biomarker to target antigens for specific immunotherapy in OSCC. This evidence concerns the gene ERBB2 and oral cavity squamous cell carcinoma.